The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.

@article{Kozuka2018ThePO,
  title={The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-na{\"i}ve patients with chronic HCV genotype 1b infection in a real-world cohort.},
  author={Ritsuzo Kozuka and Hoang Xuan Hai and Hideki Motoyama and Atsushi Hagihara and Hiroshi Fujii and Sawako Uchida-Kobayashi and Hiroyasu Morikawa and Masaru Enomoto and Yoshiki Murakami and Norifumi Kawada and A Tamori},
  journal={Journal of viral hepatitis},
  year={2018},
  volume={25 5},
  pages={
          535-542
        }
}
It is unclear whether multiple nonstructural (NS) 5A resistance-associated substitutions (RASs) correlate with the outcome of sofosbuvir (SOF) and ledipasvir (LDV) therapy. We investigated the effects of multiple NS5A RASs in NS5A inhibitor-naïve patients with chronic hepatitis C virus genotype 1b infection treated with SOF/LDV. In 313 patients treated with SOF/LDV, we assessed the effects of multiple NS5A RASs on the sustained virological response (SVR). RASs at L28, R30, L31, Q54, P58, Q62… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS